Loading clinical trials...
Loading clinical trials...
This is an open label phase I study of Inotuzumab Ozogamicin, an antibody-targeted intravenous chemotherapy agent composed of a CD22-targeted antibody linked to calicheamicin, in combination with the ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Cristiana Sessa
NCT05705570 · Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, and more
NCT06552559 · B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, and more
NCT06220097 · B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory
NCT04531046 · B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent
NCT04214886 · B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, and more
InselSpital, Universitätsspital Bern
Bern, Canton of Bern
Oncology Institute of Southern Switzerland
Bellinzona, Canton Ticino
Kantonsspital St.Gallen
San Gallen, San Gallen
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions